We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current AXIM market cap is 2.72M. The company's latest EPS is USD -0.0339 and P/E is -0.29.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 799k | 0 | 60k | 9k | 39k |
| Operating Income | -6.51M | -4.95M | -8.01M | -4.65M | -2.75M |
| Net Income | -6.45M | -6.29M | -16.03M | -6.24M | -8.06M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.69M | 11.31M | 5.32M | 4.21M | 4.12M |
| Total Liabilities | 8.45M | 9.75M | 7.66M | 9.04M | 11.78M |
| Total Equity | -6.76M | 1.57M | -2.34M | -4.83M | -7.66M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -5.02M | -3.22M | -2.49M | -2.04M | -1.03M |
| Investing | 349k | 10k | -50k | -9k | N/A |
| Financing | 3.38M | 3.15M | 2.53M | 1.65M | 1.14M |
| Market Cap | 2.72M |
| Price to Earnings Ratio | -0.29 |
| Price to Sales Ratio | 50 |
| Price to Cash Ratio | 14.29 |
| Price to Book Ratio | -0.31 |
| Dividend Yield | - |
| Shares Outstanding | 237.65M |
| Average Volume (1 week) | 153.09k |
| Average Volume (1 Month) | 419.67k |
| 52 Week Change | -56.79% |
| 52 Week High | 0.0399 |
| 52 Week Low | 0.009 |
| Spread (Intraday) | 0 (7.56%) |
| Company Name | Axim Biotechnologies Inc (QB) |
| Address |
401 ryland st reno, nevada 89502 |
| Website | https://www.aximbiotech.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
